Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Phase I: To Determine the Maximum Tolerated Dose (MTD)”

101 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 101 results

Early research (Phase 1)Ended earlyNCT01668550
What this trial is testing

A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours

Who this might be right for
Advanced Solid Tumours
Cancer Research UK 43
Early research (Phase 1)WithdrawnNCT04797468
What this trial is testing

The CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Who this might be right for
Advanced Solid Tumor
Shanghai Henlius Biotech
Early research (Phase 1)Study completedNCT01955564
What this trial is testing

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

Who this might be right for
Schizophrenia
Newron Pharmaceuticals SPA 54
Early research (Phase 1)Looking for participantsNCT04234048
What this trial is testing

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Who this might be right for
T-cell LymphomaCutaneous/Peripheral T-Cell LymphomaPeripheral T-cell Lymphoma+8 more
SciTech Development, Inc. 46
Testing effectiveness (Phase 2)Study completedNCT00708292
What this trial is testing

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Novartis Pharmaceuticals 29
Early research (Phase 1)Study completedNCT01117623
What this trial is testing

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Who this might be right for
Neoplasm
Bayer 86
Early research (Phase 1)Study completedNCT00124189
What this trial is testing

Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

Who this might be right for
Chronic Lymphoproliferative Diseases
Geron Corporation 48
Early research (Phase 1)Looking for participantsNCT07061626
What this trial is testing

Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma

Who this might be right for
EpendymomaHigh Grade Gliomas
Cerenome 56
Early research (Phase 1)Active Not RecruitingNCT05034497
What this trial is testing

Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Who this might be right for
Leptomeningeal Metastasis
Cerenome 18
Early research (Phase 1)Study completedNCT00676299
What this trial is testing

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Who this might be right for
Protein Kinase InhibitorsAntineoplastic ProtocolsClinical Trial, Phase 1+4 more
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 19
Early research (Phase 1)UnknownNCT03468751
What this trial is testing

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Henlix, Inc 30
Testing effectiveness (Phase 2)Ended earlyNCT00179725
What this trial is testing

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Who this might be right for
Ovarian Cancer
Celgene Corporation 60
Early research (Phase 1)Study completedNCT00941863
What this trial is testing

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Who this might be right for
Carcinoma
Bayer 158
Early research (Phase 1)Looking for participantsNCT05365659
What this trial is testing

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Who this might be right for
B-cell Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaFollicular Lymphoma+2 more
Iksuda Therapeutics Ltd. 140
Testing effectiveness (Phase 2)Study completedNCT00003732
What this trial is testing

Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer

Who this might be right for
Ovarian Cancer
Rigshospitalet, Denmark 80
Early research (Phase 1)Study completedNCT03292783
What this trial is testing

This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

Who this might be right for
Advanced Solid Tumors
ABL Bio, Inc. 45
Early research (Phase 1)Enrolling By InvitationNCT06169579
What this trial is testing

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

Who this might be right for
Advanced Solid Tumor
Shenzhen NewDEL Biotech, Co., Ltd 96
Early research (Phase 1)WithdrawnNCT03443622
What this trial is testing

Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors

Who this might be right for
Refractory Solid Tumor
SupremeCure Pharma Inc.
Early research (Phase 1)Ended earlyNCT01930292
What this trial is testing

Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies

Who this might be right for
Solid Tumors
Debiopharm International SA 31
Early research (Phase 1)Looking for participantsNCT05872295
What this trial is testing

IKS014 in Advanced Solid Tumors That Express HER2

Who this might be right for
Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd. 165
Next Page